3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
36
Magnetic Resonance Spectroscopy
31
Cyclophosphamide
26
Doxorubicin
23
Biopsy
22
pembrolizumab
21
Temozolomide
21
X-Rays
17
Radiotherapy
17
Radiation
16
Nivolumab
13
atezolizumab
12
Vincristine
12
Phantoms, Imaging
12
Irinotecan
12
Ifosfamide
12
Gemcitabine
12
fludarabine
11
cabozantinib
10
liposomal doxorubicin
8
Surgical Procedures, Operative
8
Ipilimumab
8
Etoposide
8
Bevacizumab
8
Paclitaxel
7
Immunoglobulin G
7
Carboplatin
7
palbociclib
6
olaparib
6
fludarabine phosphate
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
sarilumab
×
Sarcoma
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled